Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

• DOI: 10.1182/bloodadvances.2021006006
• Publication Date: 2021-11-09T22:10:41Z
• Authors: Paola Guglielmelli; Arianna Ghirardi; Alessandra Carobbio; Arianna Masciulli; Chiara Maccari; Barbara Mora; Elisa Rumi; Ana Triguero; Maria Chiara Finazzi; Helna Pettersson; Chiara Paoli; Francesco Mannelli; Daniele Vanni; Alessandro Rambaldi; Francesco Passamonti; Alberto Alvarez-L...; Bjorn Andreasson; Alessandro M. Van...; Tiziano Barbui
• Keywords: Ruxolitinib

Survival in patients with myelofibrosis (MF), median overall survival (OS) of 6 to 7 years, is shorter than that of the general population.1 MF is also associated with profound negative effects on quality of life.